Relay Therapeutics (RLAY) Cash from Operations (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash from Operations data on file, last reported at 51112000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 30.18% year-over-year to 51112000.0 in Q1 2026; TTM through Mar 2026 was 213357000.0, a 21.56% increase from a year earlier, with the FY2025 full-year figure at 235455000.0, up 5.48% from the prior year.
• Cash from Operations for Q1 2026 stood at 51112000.0, down from 44865000.0 in the prior quarter.
• Over the last five years, Cash from Operations for RLAY reached as high as 44865000.0 in Q4 2025 and fell as low as 89188000.0 in Q4 2023.
• Historically, Cash from Operations has averaged 62675294.12 across 5 years, with a median of 62119000.0 in 2025.
• Across the five-year window, Cash from Operations sank 205.43% in 2022 and surged 35.12% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 57079000.0 in 2022, then tumbled by 56.25% to 89188000.0 in 2023, then jumped by 35.12% to 57868000.0 in 2024, then rose by 22.47% to 44865000.0 in 2025, then slipped by 13.92% to 51112000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 51112000.0 in Q1 2026, 44865000.0 in Q4 2025, and 62119000.0 in Q3 2025.